14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BDRX vs NEXR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is the stronger overall head-to-head candidate over NEXR (NEXR) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BDRX carries a Unified Composite Score of 34.7/100 (SELL) at $2.35 (N/M Forward P/E, 0.0% operating margin), whereas NEXR carries 31.0/100 (SELL) at $1.38 (N/M Forward P/E, N/A operating margin).
Defensive Composite Rating Caution: Although BDRX compares more favorably head-to-head, both BDRX (34.7/100 SELL) and NEXR (31.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BDRX vs NEXR. Trailing 12-month operating profitability (BDRX 0.0% vs NEXR N/A) and valuation multiples (BDRX N/M vs NEXR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BDRX vs NEXR Key Questions & Quantitative Answers
As of Nov 16, 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is the stronger overall head-to-head candidate over NEXR (NEXR) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BDRX carries a Unified Composite Score of 34.7/100 (SELL) at $2.35 (N/M Forward P/E, 0.0% operating margin), whereas NEXR carries 31.0/100 (SELL) at $1.38 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although BDRX compares more favorably head-to-head, both BDRX (34.7/100 SELL) and NEXR (31.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
BDRX leads the Growth & Scale pillar: BDRX posts -64.1% YoY revenue growth and +0.0% YoY earnings growth on $83,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with NEXR at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BDRX generates $83,000 in USD-normalized revenue versus N/A for NEXR. In operating R&D and SG&A reinvestment, BDRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NEXR.
BDRX screens cheaper on headline valuation multiples. BDRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 15.0x EV/Revenue (unreported EBITDA margin), whereas NEXR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BDRX (-42.0% ROE) versus NEXR (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, BDRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (5.72β · 2679% Vol realized risk). By comparison, NEXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (8.42β · 2730% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.